Kidney Stone
Conditions
Brief summary
Extracorporeal shockwave lithotripsy (ESWL) is one way to treat renal stones. In this clinical trial our goal is to evaluate if two ESWL the same week is equal good and safe to two ESWL 3 weeks regarding renal stones 8-15 mm.
Detailed description
All patients with a renal stone 8-15 mm are asked to participate. If they give consent they are randomized to ESWL with an interval of 2 days or 3 weeks. Data regarding age, gender, stone size, Hounsfield unit, skin to stone distance, urine culture, results from the follow up CT and need for auxillary interventions are extraced from the medical records.
Interventions
ESWL, two treatments with an interval of two days or three weeks.
Sponsors
Region Skane
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Randomisation to ESWL with an interval of two days and with an interval of three weeks.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All patients with a renal stone 8-15 mm who are planned for intervention -
Exclusion criteria
Those who decline to participate, those who are put under guardianship or is less than 18 years old. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to stone free status | From enrollment until closure | Number of days from the day the treatment starts until the end of follow up. |
| Complications | From enrollment until closure | Are there any differences in complications |
| Number of participants considered stone free at follow up | From enrollment until closure. | Number of participants who are stone free at the follow up after two ESWL. Stone status will be assessed with computer tomography. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Participant´s experiences | From enrollment until closure | Participant´s experiences, quality of life questionnaire. Most questions were structured as yes/ no items or included three to four predefined response options. |
Countries
Sweden
Contacts
PRINCIPAL_INVESTIGATORMagnus Wagenius, MD, PhD
University of Lund
Outcome results
None listed